246 related articles for article (PubMed ID: 11337565)
41. Diagnostic evaluation of malignant head and neck cancer by F-18-FDG PET compared to CT/MRI.
Nowak B; Di Martino E; Jänicke S; Cremerius U; Adam G; Zimny M; Reinartz P; Büll U
Nuklearmedizin; 1999; 38(8):312-8. PubMed ID: 10615664
[TBL] [Abstract][Full Text] [Related]
42. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma.
Delbeke D; Rose DM; Chapman WC; Pinson CW; Wright JK; Beauchamp RD; Shyr Y; Leach SD
J Nucl Med; 1999 Nov; 40(11):1784-91. PubMed ID: 10565771
[TBL] [Abstract][Full Text] [Related]
43. 18F-FDG accumulation with PET for differentiation between benign and malignant lesions in the thorax.
Demura Y; Tsuchida T; Ishizaki T; Mizuno S; Totani Y; Ameshima S; Miyamori I; Sasaki M; Yonekura Y
J Nucl Med; 2003 Apr; 44(4):540-8. PubMed ID: 12679397
[TBL] [Abstract][Full Text] [Related]
44. Grading of tumors and tumorlike lesions of bone: evaluation by FDG PET.
Schulte M; Brecht-Krauss D; Heymer B; Guhlmann A; Hartwig E; Sarkar MR; Diederichs CG; Von Baer A; Kotzerke J; Reske SN
J Nucl Med; 2000 Oct; 41(10):1695-701. PubMed ID: 11038000
[TBL] [Abstract][Full Text] [Related]
45. Whole-body tumor imaging using PET and 2-18F-fluoro-L-tyrosine: preliminary evaluation and comparison with 18F-FDG.
Hustinx R; Lemaire C; Jerusalem G; Moreau P; Cataldo D; Duysinx B; Aerts J; Fassotte MF; Foidart J; Luxen A
J Nucl Med; 2003 Apr; 44(4):533-9. PubMed ID: 12679396
[TBL] [Abstract][Full Text] [Related]
46. Role of repeated F-18 fluorodeoxyglucose imaging in management of patients with bone and soft tissue sarcoma.
el-Zeftawy H; Heiba SI; Jana S; Rosen G; Salem S; Santiago JF; Abdel-Dayem HM
Cancer Biother Radiopharm; 2001 Feb; 16(1):37-46. PubMed ID: 11279796
[TBL] [Abstract][Full Text] [Related]
47. 18FDG PET scanning of benign and malignant musculoskeletal lesions.
Feldman F; van Heertum R; Manos C
Skeletal Radiol; 2003 Apr; 32(4):201-8. PubMed ID: 12652335
[TBL] [Abstract][Full Text] [Related]
48. [Value of dual-time-point (18)F-fluorodeoxyglucose integrated positron emission and computed tomography in differentiation of malignant from benign gastrointestinal diseases].
Xu XX; Cheng J; Xu WG; Dai D; Song XY; Ma WC; Zhu L; Zhu X
Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):364-8. PubMed ID: 22883458
[TBL] [Abstract][Full Text] [Related]
49. [The application of 18F-fluorodeoxyglucose positron emission tomography in the diagnosis and staging of lung cancer].
Xu HF; Liu Y; Zhang JH; Zhou RS; Zhou FH; Yuan MH
Zhonghua Jie He He Hu Xi Za Zhi; 2005 Feb; 28(2):108-11. PubMed ID: 15854393
[TBL] [Abstract][Full Text] [Related]
50. Evaluation of fluorodeoxyglucose positron emission tomography in the management of soft-tissue sarcomas.
Lucas JD; O'Doherty MJ; Wong JC; Bingham JB; McKee PH; Fletcher CD; Smith MA
J Bone Joint Surg Br; 1998 May; 80(3):441-7. PubMed ID: 9619933
[TBL] [Abstract][Full Text] [Related]
51. Quantitative PET studies in pretreated melanoma patients: a comparison of 6-[18F]fluoro-L-dopa with 18F-FDG and (15)O-water using compartment and noncompartment analysis.
Dimitrakopoulou-Strauss A; Strauss LG; Burger C
J Nucl Med; 2001 Feb; 42(2):248-56. PubMed ID: 11216523
[TBL] [Abstract][Full Text] [Related]
52. [(18)F]FMISO and [(18)F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression.
Rajendran JG; Wilson DC; Conrad EU; Peterson LM; Bruckner JD; Rasey JS; Chin LK; Hofstrand PD; Grierson JR; Eary JF; Krohn KA
Eur J Nucl Med Mol Imaging; 2003 May; 30(5):695-704. PubMed ID: 12632200
[TBL] [Abstract][Full Text] [Related]
53. Functional imaging and detection of local recurrence in soft tissue sarcomas by positron emission tomography.
Schwarzbach M; Willeke F; Dimitrakopoulou-Strauss A; Strauss LG; Zhang YM; Mechtersheimer G; Hinz U; Lehnert T; Herfarth C
Anticancer Res; 1999; 19(2B):1343-9. PubMed ID: 10365104
[TBL] [Abstract][Full Text] [Related]
54. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG.
Chen W; Cloughesy T; Kamdar N; Satyamurthy N; Bergsneider M; Liau L; Mischel P; Czernin J; Phelps ME; Silverman DH
J Nucl Med; 2005 Jun; 46(6):945-52. PubMed ID: 15937304
[TBL] [Abstract][Full Text] [Related]
55. 18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy.
Chen W; Silverman DH; Delaloye S; Czernin J; Kamdar N; Pope W; Satyamurthy N; Schiepers C; Cloughesy T
J Nucl Med; 2006 Jun; 47(6):904-11. PubMed ID: 16741298
[TBL] [Abstract][Full Text] [Related]
56. Value of FDG PET/CT in Patient Management and Outcome of Skeletal and Soft Tissue Sarcomas.
Sheikhbahaei S; Marcus C; Hafezi-Nejad N; Taghipour M; Subramaniam RM
PET Clin; 2015 Jul; 10(3):375-93. PubMed ID: 26099673
[TBL] [Abstract][Full Text] [Related]
57. Fluorine-18-fluorodeoxyglucose PET versus thallium-201 scintigraphy evaluation of thyroid tumors.
Uematsu H; Sadato N; Ohtsubo T; Tsuchida T; Nakamura S; Sugimoto K; Waki A; Takahashi N; Yonekura Y; Tsuda G; Saito H; Hayashi N; Yamamoto K; Ishii Y
J Nucl Med; 1998 Mar; 39(3):453-9. PubMed ID: 9529291
[TBL] [Abstract][Full Text] [Related]
58. Assessment of quantitative FDG PET data in primary colorectal tumours: which parameters are important with respect to tumour detection?
Strauss LG; Klippel S; Pan L; Schönleben K; Haberkorn U; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2007 Jun; 34(6):868-77. PubMed ID: 17219134
[TBL] [Abstract][Full Text] [Related]
59. Quantitative [F-18]fluorodeoxyglucose positron emission tomography in pretreatment and grading of sarcoma.
Eary JF; Conrad EU; Bruckner JD; Folpe A; Hunt KJ; Mankoff DA; Howlett AT
Clin Cancer Res; 1998 May; 4(5):1215-20. PubMed ID: 9607579
[TBL] [Abstract][Full Text] [Related]
60. Comparison of fluorine-18-FDG PET and technetium-99m-MIBI SPECT in evaluation of musculoskeletal sarcomas.
Garcia R; Kim EE; Wong FC; Korkmaz M; Wong WH; Yang DJ; Podoloff DA
J Nucl Med; 1996 Sep; 37(9):1476-9. PubMed ID: 8790197
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]